School of Medicine
Showing 1-10 of 15 Results
-
Kenneth Mahaffey
Professor of Medicine (Cardiovascular Medicine)
BioClinical Focus: Cardiovascular Medicine: Atrial Fibrillation; Chronic CAD; ACS;
Research Focus:
My primary research interest is the design and conduct of multicenter clinical trials and analyses of important clinical cardiac issues using large patient databases. My research focuses on novel anticoagulation agents for the treatment of acute coronary syndromes and atrial fibrillation, the study of agents targeted to protect the myocardium during reperfusion therapy for acute myocardial infarction, and the evaluation of cardiovascular safety of diabetic therapies. I am also interested in the methodology of clinical trials. Current research activities include standardization of the definition of myocardial infarction used in clinical trials, the adjudication of suspected clinical endpoint events by Clinical Event Committees (CEC), and the efficient operational conduct of large multinational clinical trials.
Administrative Focus: Associate Dean, Clinical Research School of Medicine; Vice Chair of Clinical Research Department of Medicine; Director Stanford Center for Clinical Research; Member of the Stanford IRB
Professional Training:
1985 Stanford University, BS Chemistry
1989 University of Washington, MD
1993 University of Arizona, Internship/Residency/Chief Residency
1996 Duke University, Fellowship in Cardiology
1996 Duke University, Faculty in Cardiology
2013 Stanford University, Faculty Cardiovascular Medicine -
Anurag Mairal
Adjunct Professor, Medicine - Cardiovascular Medicine
BioDr. Anurag Mairal is an Adjunct Professor of Medicine and the Director, Global Outreach Programs at Stanford Byers Center for Biodesign, Stanford University. He is also a Faculty Fellow and Lead for Technology Innovation and Impact at Center for Innovation in Global Health. In these roles, he leads initiatives focused on applying the biodesign process to resource-constrained se ttings globally. Further, he facilitates opportunities for students, faculty and fellows at Stanford to work on global healthcare needs. He is founding co-Director for MED 232, Global Health: Scaling Health Technology Innovations in Low Resource Settings, and was part of the founding faculty team for BIOE 371, Global Biodesign: Medical Technology in an International Context, graduate-level courses offered to engineering, business, and medical students at Stanford University. Earlier, he served as Associate Director for the Stanford-India Biodesign and Singapore-Stanford Biodesign programs. He serves as the Founding Chair of BME IDEA APAC, a community of medtech innovation programs in Asia Pacific, partnering closely with the industry and academia in the region. He is also an Honorary Professor at University of Cape Town, South Africa. Concurrently, he is a co-founder and Executive Vice President of Orbees Medical, a SF Bay Area-based strategy consulting firm serving global healthcare industry, with a focus on medtech, pharmaceutical, and digital health industry.
Dr. Mairal has an extensive background in medical technology development and commercialization, collaborating with partners in the U.S., India, China, and other emerging markets to advance product development, manufacturing, and distribution. Recently, he took a sabbatical for two years to take a senior leadership role at PATH, a major global health nonprofit based in Seattle. In this role, he oversaw research and development, commercialization, and implementation of technologies in PATH’s medical devices, diagnostics, and digital health divisions. Previously, he held several positions at Johnson & Johnson, including Business Development Director and Product Director for structural heart, cardiology, and peripheral vascular products at Cordis. Before joining J&J, he was a Group Leader and a Process Development Manager at Membrane Technology and Research (MTR). At MTR, he was responsible for business development, strategic alliances, and product development in the bioseparations area. An active mentor to entrepreneurs and industry professionals, he serves as the chair of PATH’s Bay Area Leadership Council; chair of the board at EPPIC Global Network; chair of Faculty Alumni Network at IIT Bombay Heritage Foundation; and President of Sewa International - Bay Area.
Dr. Mairal earned a PhD in chemical engineering from the University of Colorado at Boulder and an MBA from the Haas School of Business at the University of California at Berkeley. He also holds an MS in chemical engineering from the Indian Institution of Technology in Mumbai and a BS in chemical engineering from National Institute of Technology, Raipur. Dr. Mairal was a post-doctoral fellow at the University of Twente, Netherlands and at University of Michigan, Ann Arbor. At BerkeleyHaas, he was a founding co-Chairman of the South Asia Business Conference and Chair of the Biotech Panel for the Asia Business Conference. His work has been published in more than 30 publications, and he has seven issued patents. -
Joshua Makower
Yock Family Professor and Professor of Bioengineering
Current Research and Scholarly InterestsDr. Josh Makower is the Boston Scientific Applied Bioengineering Professor of Medicine and of Bioengineering at the Stanford University Schools of Medicine and Engineering and the Director of the Stanford Byers Center for Biodesign, the program he co-founded with Dr. Paul Yock twenty years ago. Josh helped create the fundamental structure of the Center’s core curriculum and is the chief architect of what is now called “The Biodesign Process.” Over the past 20 years since Josh and Paul founded Biodesign, this curriculum and the associated textbook has been used at Stanford and across the world to train hundreds of thousands of students, faculty and industry leaders on the Biodesign process towards the advancement of medical innovation for the improvement of patient care. Josh has practiced these same techniques directly as the Founder & Executive Chairman of ExploraMed, a medical device incubator, creating 9 companies since 1995. Transactions from the ExploraMed portfolio include NeoTract, acquired by Teleflex, Acclarent, acquired by J&J, EndoMatrix, acquired by C.R. Bard & TransVascular, acquired by Medtronic. Other ExploraMed/NEA ventures include Moximed, NC8 and Willow. Josh is also a Special Partner at NEA where he supports the healthcare team and medtech/healthtech investing practice. Josh serves on the boards of Allay Therapeutics, Revelle Aesthetics, Setpoint Medical, DOTS Technologies, Eargo, ExploraMed, Intrinsic Therapeutics, Moximed, Willow and Coravin. Josh holds over 300 patents and patent applications. He received an MBA from Columbia University, an MD from the NYU School of Medicine, a bachelor’s degree in Mechanical Engineering from MIT. Josh is a Member of the National Academy of Engineering and the College of Fellows of The American Institute for Medical and Biological Engineering and was awarded the Coulter Award for Healthcare Innovation by the Biomedical Engineering Society in 2018.
-
Michael V. McConnell, MD, MSEE
Clinical Professor, Medicine - Cardiovascular Medicine
Current Research and Scholarly InterestsMy imaging research has involved clinical and molecular Imaging of cardiovascular disease, with a focus on coronary and vascular diseases, including atherosclerosis, aortic aneurysms, and vascular inflammation.
My prevention research has involved innovative technologies to reduce coronary and vascular disease, including early disease detection plus leveraging mobile health and AI to enhance heart heart in patients and populations. -
Jessica Lee Mega
Affiliate, Medicine - Med/Cardiovascular Medicine
BioJessica L. Mega, MD, MPH is a leader at the intersection of technology, life science, and health care. She is a Cardiologist at Stanford and serves on the Advisory Board for Stanford's Center for Digital Health. She is a Co-Founder of Alphabet's Verily, and she is on the Board of Directors at Boston Scientific and Danaher Corporation, as well as the Board of Advisors for Research!America and the Duke-Margolis Center for Health Policy.
As a faculty member at Harvard Medical School, a Senior Investigator with the TIMI Study Group, and a Cardiologist at Brigham and Women’s Hospital, Dr. Mega led large, international, randomized trials evaluating novel therapies. She also directed the TIMI Study Group’s Genomics Program, demonstrating and testing the role of CYP2C19 genetic variants on antiplatelet medications, a key pharmacogenetic finding. She has published manuscripts in the New England Journal of Medicine, Lancet, and JAMA. She served as an Advisor for the California Governor’s Precision Medicine Initiative.
Dr. Mega is a graduate of Stanford University, Yale University School of Medicine, and Harvard School of Public Health. She completed Internal Medicine Residency at Brigham and Women’s Hospital and Cardiovascular Fellowship at Massachusetts General Hospital. She is board certified in Internal Medicine and Cardiology. She has won the Laennec Society, Samuel A. Levine, and Douglas P. Zipes Awards, and she is a Fellow of the American Heart Association (AHA) and the American College of Cardiology (ACC). -
Hector Rodrigo Mendez
Postdoctoral Scholar, Cardiovascular Medicine
BioDr. Hector Rodrigo Mendez is a Medical Geneticist from Argentina. Rodrigo completed a residency program in Medical Genetics at Centro Nacional de Genetica Medica – ANLIS (Buenos Aires, Argentina) and a Master’s program in Medical Molecular Biology at Buenos Aires University.
Rodrigo continued his scientific career at a German Genomic Start-up, working as a human geneticist and providing his experience in rare disorders, genomic data (WGS/WES/gene panels) analysis, variant interpretation, and its integration with a deep focus on genotype-phenotype correlation.
Rodrigo’s areas of expertise are rare disorders, NGS technology, Whole Genome Sequencing analysis, and ACMG interpretation guidelines, and his research aims are:
- Collection and analysis of clinical data through deep-learning phenotyping approaches.
- Multi-omic data integration to elucidate complex and rare genetic disorders.
- International collaborations to break down barriers to research participation amongst those who have been under-represented.
At Stanford University, under the supervision of Dr. Matthew Wheeler, he is conducting his postdoctoral research studies to achieve his scientific goals.
